ArticleBMC neuroscience2026
Slc6a9 is distributed in glial cells and neurons across several nervous system regions, whereas Slc6a5 is more restricted to neurons in the caudal brain.
Article in BMC neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe glycinergic system constitutes a main source of inhibitory regulation in the central nervous system. Glycine transporters (GLYT1 and GLYT2), encoded by Slc6a9 and Slc6a5, respectively, are responsible for glycine reuptake and clearance from the synaptic cleft, thereby maintaining neurotransmitter homeostasis. Emerging evidence from pharmacological and mechanistic studies has highlighted GLYTs as promising therapeutic targets for psychiatric disorders and persistent pain. Nevertheless, data on anatomical and cellular distribution of GLYTs and sex-dependent differences in GLYT expression remain limited.
methodsTo address this gap, the aim of this study was to examine the Slc6a9 and Slc6a5 mRNA expression across mouse brain regions and peripheral organs using three complementary approaches focusing on mRNA expression: re-analysis of single-cell RNA sequencing data, quantitative RT-PCR, and RNAscope.
resultsBoth genes were detected in multiple brain regions, with Slc6a9 exhibiting a broader distribution in both glial cells and neurons, while Slc6a5 was more restricted to neurons. Sex-dependent differences were detected for Slc6a9 in the amygdala and thalamus, liver, intestine, spleen, kidney and genitalia using quantitative RT-PCR, and for Slc6a5 in the cortex, striatum, hippocampus, and spinal cord using quantitative RT-PCR. Spatial analysis of the glycine transporters showed that Slc6a9 can be found in several brain regions spanning the rostral to the caudal axis, in both glial cells and neurons, while Slc6a5 was more restricted to the caudal brain regions.
conclusionsIn general, in regions where differences were detected using quantitative RT-PCR, higher expression levels were observed in male mice. Moreover, Slc6a9 expression was found to occur in both glial cells, such as astrocytes, oligodendrocytes and ependymal cells, as well as both excitatory and inhibitory neurons, while Slc6a5 mainly occurred in inhibitory neurons. These findings provide novel insights into the spatial and sex-dependent expression of glycine transporters.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.